Cost-effectiveness of Competing Strategies for Management of Recurrent Clostridium difficile Infection: A Decision Analysis
Open Access
- 31 March 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 58 (11) , 1507-1514
Abstract
Clostridium difficile infection (CDI) causes considerable morbidity and is characterized by substantial risk of recurrence. In a decision model of strategies to treat recurrent CDI, initial treatment with fecal microbiota transplant using colonoscopic delivery is the most cost-effective approach. Background. Clostridium difficile infection (CDI) is an important cause of morbidity and healthcare costs, and is characterized by high rates of disease recurrence. The cost-effectiveness of newer treatments for recurrent CDI has not been examined, yet would be important to inform clinical practice. The aim of this study was to analyze the cost effectiveness of competing strategies for recurrent CDI. Methods. We constructed a decision-analytic model comparing 4 treatment strategies for first-line treatment of recurrent CDI in a population with a median age of 65 years: metronidazole, vancomycin, fidaxomicin, and fecal microbiota transplant (FMT). We modeled up to 2 additional recurrences following the initial recurrence. We assumed FMT delivery via colonoscopy as our base case, but conducted sensitivity analyses based on different modes of delivery. Willingness-to-pay threshold was set at $50 000 per quality-adjusted life-year. Results. At our base case estimates, initial treatment of recurrent CDI using FMT colonoscopy was the most cost-effective strategy, with an incremental cost-effectiveness ratio of $17 016 relative to oral vancomycin. Fidaxomicin and metronidazole were both dominated by FMT colonoscopy. On sensitivity analysis, FMT colonoscopy remained the most cost-effective strategy at cure rates >88.4% and CDI recurrence rates Conclusions. In this decision analysis examining treatment strategies for recurrent CDI, we demonstrate that FMT colonoscopy is the most cost-effective initial strategy for management of recurrent CDI.Keywords
This publication has 44 references indexed in Scilit:
- Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus VancomycinClinical Infectious Diseases, 2012
- The economic burden of Clostridium difficileClinical Microbiology and Infection, 2012
- Fecal Microbiota Transplantation for Relapsing Clostridium difficile Infection in 26 PatientsJournal of Clinical Gastroenterology, 2012
- Hospital-acquired Clostridium difficile infection: determinants for severe diseaseEuropean Journal of Clinical Microbiology & Infectious Diseases, 2011
- Treating Clostridium difficile Infection With Fecal Microbiota TransplantationClinical Gastroenterology and Hepatology, 2011
- Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent InfectionsClinical Infectious Diseases, 2011
- Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazineBMC Health Services Research, 2011
- A Prospective Study of Risk Factors and Historical Trends in Metronidazole Failure for Clostridium difficile InfectionClinical Gastroenterology and Hepatology, 2008
- A Comparison of Vancomycin and Metronidazole for the Treatment of Clostridium difficile-Associated Diarrhea, Stratified by Disease SeverityClinical Infectious Diseases, 2007
- Impact of Emergency Colectomy on Survival of Patients With Fulminant Clostridium difficile Colitis During an Epidemic Caused by a Hypervirulent StrainAnnals of Surgery, 2007